• Asian Pacific Journal of Cancer Prevention
• /
• 제14권9호
• /
• pp.5037-5041
• /
• 2013

Accumulated evidence has indicated that Ephrin A1 (EFNA1) is associated with angiogenesis and tumorigenesis in various types of malignancies, including colorectal cancer (CRC). In the current study, we performed an online search using the public microarray database to investigate whether EFNA1 expression might be altered in CRC tissues. We then conducted a case-control study including 306 subjects (102 cases and 204 well-matched controls) in Xiaoshan County to assess any association between genetic polymorphisms in EFNA1 and CRC susceptibility. Searches in the Oncomine expression profiling database revealed EFNA1 to be overexpressed in CRC tissue compared with adjacent normal tissue. The rs12904 G-A variant located in the 3' untranslated region (UTR) of EFNA1 was observed to be associated with CRC susceptibility. Compared with the AA homozygous genotype, those carrying GA genotype had a decreased risk of developing CRC (odds ratio (OR)=0.469, 95% confidence interval (CI): 0.225-0.977, and P=0.043). The association was stronger among smokers and tea drinkers, however, no statistical evidence of interaction between rs12904 polymorphism and smoking or tea drinking on CRC risk was found. Our results suggest that EFNA1 is involved in colorectal tumorigenesis, and rs12904 A>G polymorphism in the 3' UTR of EFNA1 is associated with CRC susceptibility. Larger studies and further mechanistic investigations are warranted to confirm our findings.

• 대한종양외과학회지
• /
• 제14권2호
• /
• pp.83-88
• /
• 2018

Purpose: Double primary colorectal cancer (CRC) and gastric cancer (GC) represent the most common multiple primary malignant tumors (MPMT) in Korea. The recognition and screening of hidden malignancies other than the primary cancer are critical. This study aimed to investigate the clinicopathologic characteristics and survival rates in patients with synchronous or metachronous double primary CRC and GC. Methods: Between January 1994 and May 2018, 11,050 patients were diagnosed with CRC (n=5,454) or GC (n=5,596) at Gil Medical Center. MPMT and metastatic malignant tumors were excluded from this study. A total of 103 patients with double primary CRC and GC were divided into two groups: the synchronous group (n=40) and the metachronous group (n=63). The incidence, clinicopathologic characteristics, and survival rate of the two groups were analyzed. Results: The incidence of synchronous and metachronous double primary CRC and GC was 0.93%. Double primary CRC and GC commonly occurred in male patients aged over 60 years with low comorbidities and minimal previous cancer history. There were significant differences between the synchronous and metachronous groups in terms of age, morbidity, and overall survival. Metachronous group patients were 6 years younger on average (P=0.009), had low comorbidities (P=0.008), and showed a higher 5-year overall survival rate (94.8% and 61.3%, P<0.001) in contrast to synchronous group. Conclusion: When primary cancer (CRC or GC) is detected, it is important to be aware of the possibility of the second primary cancer (GC or CRC) development at that time or during follow-up to achieve early detection and better prognosis.

• Journal of Cancer Prevention
• /
• 제23권4호
• /
• pp.183-190
• /
• 2018

Background: As the number of big-cohort studies increases, validation becomes increasingly more important. We aimed to validate administrative database categorized as colorectal cancer (CRC) by the International Classification of Disease (ICD) 10th code. Methods: Big-cohort was collected from Clinical Data Warehouse using ICD 10th codes from May 1, 2003 to November 30, 2016 at Seoul National University Bundang Hospital. The patients in the study group had been diagnosed with cancer and were recorded in the ICD 10th code of CRC by the National Health Insurance Service. Subjects with codes of inflammatory bowel disease or tuberculosis colitis were selected for the control group. For the accuracy of registered CRC codes (C18-21), the chart, imaging results, and pathologic findings were examined by two reviewers. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for CRC were calculated. Results: A total of 6,780 subjects with CRC and 1,899 control subjects were enrolled. Of these patients, 22 subjects did not have evidence of CRC by colonoscopy, computed tomography, magnetic resonance imaging, or positron emission tomography. The sensitivity and specificity of hospitalization data for identifying CRC were 100.00% and 98.86%, respectively. PPV and NPV were 99.68% and 100.00%, respectively. Conclusions: The big-cohort database using the ICD 10th code for CRC appears to be accurate.

• Yonsei Medical Journal
• /
• 제59권9호
• /
• pp.1034-1040
• /
• 2018

Purpose: This study aimed to investigate inequalities in colorectal cancer (CRC) screening rates in Korea and trends therein using the slope index of inequality (SII) and relative index of inequality (RII) across income and education groups. Materials and Methods: Data from the Korean National Cancer Screening Survey, an annually conducted, nationwide cross-sectional survey, were utilized. A total of 17174 men and women aged 50 to 74 years were included for analysis. Prior experience with CRC screening was defined as having either a fecal occult blood test within the past year or a lifetime colonoscopy. CRC screening rates and annual percentage changes (APCs) were evaluated. Then, SII and RII were calculated to assess inequality in CRC screening for each survey year. Results: CRC screening rates increased from 23.4% in 2005 to 50.9% in 2015 (APC, 7.8%; 95% CI, 6.0 to 9.6). Upward trends in CRC screening rates were observed for all age, education, and household income groups. Education inequalities were noted in 2009, 2014, and overall pooled estimates in both indices. Income inequalities were inconsistent among survey years, and overall estimates did not reach statistical significance. Conclusion: Education inequalities in CRC screening among men and women aged 50 to 74 years were observed in Korea. No apparent pattern, however, was found for income inequalities. Further studies are needed to thoroughly outline socio-economic inequalities in CRC screening.

• BMB Reports
• /
• 제48권4호
• /
• pp.217-222
• /
• 2015

Colorectal cancer (CRC) is the third most common cancer and the fourth most common cause of cancer-related death worldwide. Distant metastasis is a major cause of mortality in CRC. MicroRNAs (miRNAs) are small non-coding RNA molecules involved in the post-transcriptional and translational regulation of gene expression. Many miRNAs are aberrantly expressed in cancer and influence tumor progression. Accumulating studies suggest that multiple miRNAs are actively involved in the CRC metastasis process. Thus, we aim to introduce the role of miRNAs in multi-steps of CRC metastasis, including cancer cell invasion, intravasation, circulation, extravasation, colonization, angiogenesis, and epithelial-mesenchymal transition (EMT). Moreover, we suggest the potential application of miRNAs as biomarkers for CRC patients with metastasis. [BMB Reports 2015; 48(4): 217-222]

• Corrosion Science and Technology
• /
• 제14권6호
• /
• pp.280-287
• /
• 2015

The German Guidelines for stainless steel in buildings (Z.30.3-6) issued by the German Institute for Building Technology (DIBt) categorizevarious stainless steel grades into five corrosion resistance classes (CRCs). Only 21 frequently used grades are approved and assigned to these CRCs. To assign new or less commonly used materials, a large program of outdoor exposure tests and laboratory tests is required. The present paper shows theresults of stress corrosion cracking (SCC) tests that can distinguish between different CRCs. Slow strain rate tests (SSRT) were performedin various media and at different temperatures. CRC IV could be distinguished from CRC II and CRC III with a 31.3 % $Cl^-$ as $MgCl_2$ solutionat $140^{\circ}C$. CRC II and CRC III could be differentiated by testing in a 30% $Cl^-$ as $MgCl_2$ solutionat $100^{\circ}C$.

• 한국건축시공학회:학술대회논문집
• /
• 한국건축시공학회 2018년도 추계 학술논문 발표대회
• /
• pp.163-164
• /
• 2018

In this study, the adhesion performance of the adhesive between the concrete base and the fiber panel was verified through experiments. Attachment to all three types by applying adhesive to panel and attaching to CRC board surface, method of applying adhesive to CRC board surface by panel, method of applying adhesive on panel and CRC board surface respectively, As a result of the performance test, the adhesive strength of the panel attached to the panel on the CRC board after the application of the adhesive was highest on both the back surface of the panel and the surface of the CRC board.

• 융합신호처리학회 학술대회논문집
• /
• 한국신호처리시스템학회 2003년도 하계학술대회 논문집
• /
• pp.205-208
• /
• 2003

본 논문에서는 현재 산업현장에서 사용되고 있는 유선 콘트롤러와 무선 콘트롤러의 문제점을 보완하기 위해 컨볼루션 부호와 CRC부호를 적용한 무선 콘트롤러를 구현하였다. 콘트롤러의 제어를 위해 마이크로프로세서를 이용하였으며, 송수신 프로그램에 컨볼루션 부호를 적용하였을 때와 적용하지 않았을 때의 각각의 경우에 데이터 수신율을 테스트하여 비교해 보았다. 무선 콘트롤러의 신뢰도 향상을 위해 적용한 컨볼루션 부호는 구속장 k=3, 부호율 1/2인 부호를 사용하였고, CRC 부호는 POLYNOMIAL함수를 /Χ$^{15}$ ＋Χ$^{2}$＋1로 사용하여 총 CRC비트는 16비트(2바이트)가 되게 하였다.

• 공업화학
• /
• 제32권3호
• /
• pp.253-259
• /
• 2021

Colorectal cancer (CRC) is one of the most prevalent diseases in modern society, constituting a serious threat to global health. Currently, routine clinical screening and early removal of precancerous polyps are the most successful methods for reducing CRC incidence and mortality. However, the high cost and invasive detection of sigmoidoscopy and colonoscopy limited the CRC-screening participation and prevention. The emergence of biosensors provides an inexpensive, sensitive, less invasive tool for detecting CRC disease biomarkers. This review highlights some of recent efforts made on developing biosensors with electrochemical and optical techniques targeting CRC specific protein biomarkers for early diagnosis and prognosis, potential applications, and future perspectives.

• Journal of Digestive Cancer Research
• /
• 제6권2호
• /
• pp.45-49
• /
• 2018

Colorectal cancer (CRC) is the third most common cause of cancer-related death in the world. Although the long-term outcome of patients with metastatic CRC is still poor, target therapy including anti EGFR agents and anti VEGF agents and immunotherapy including anti PD-1 antibody and anti CTLA-4 antibody have shown clinical benefits in the treatment of patient with metastatic CRC. In the future, the personalized treatment strategy based on the clinical characteristics and biologic features of patients with metastatic CRC will be necessary. In this review, we summarized the mechanisms and clinical evidences of target therapy and immunotherapy, and the guideline of clinical practice in patients with metastatic CRC.